RE: Brokers note £9.9012 Oct 2020 15:29
Numis has come out with a broker note price target of £9.90 for Synaigen today. Hence the surge.
Broker note
Compelling risk/reward: We detail the risks facing Synairgen throughout this note,
but given the strong data in Phase 2, we place the chance of Phase 3 success at 70%,
slightly above the industry average. The question then becomes what value can be
placed on a drug that treats the vulnerable and could enable a return to the old normal?
Our Bull case extends to £50/sh based on the valuations of Moderna/BioNTech with a
need for SNG001 whether or not the vaccines prove successful.